N/A N=25 Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer
Breast Carcinoma · Radiation-Induced Dermatitis
Primary: Incidence of Early Adverse Skin Reactions (EASRs) — 13; 10; 4; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=187 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Breast Cancer
Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…
Phase 2 N=20 Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
Breast Cancer · Skin Reactions Secondary to Radiation Therapy
Primary: Percent of Women Who Develop Grade 3 or 4 Radiation Dermatitis (as Defined by the Stanford Radiation Dermatitis Scoring System) During a Course of Radiation Therapy — 6…
Phase 3 N=686 Oral Curcumin for Radiation Dermatitis
Radiation-induced Dermatitis
Primary: Mean Radiation Dermatitis Severity Score — 2.02; 1.99 units on a scale — p=0.6555
N/A N=34 MediHoney for Radiation Dermatitis
Breast Cancer · Radiation Dermatitis
Primary: Number of Participants Whom Received Medihoney Treatment and Were Analyzed Weekly for Skin Changes While Undergoing Radiation Therapy — 15; 15; 15; 15 participants
Phase 2 N=35 Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients
Breast Cancer
Primary: Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients — 2.6; 3.4 units on a scale — p=0.0077
Phase 3 N=132 Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Head and Neck Carcinoma · Radiation-Induced Dermatitis
Primary: Radiation Dermatitis — 34; 36 Participants — p=.8872
Phase 2 N=191 Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Breast Carcinoma · Pain · Radiation-Induced Dermatitis
Primary: Mean Radiation Dermatitis Severity (RDS) Score. Range: 0 (no Dermatitis) - 4 (Violaceous Erythema With Diffuse Desquamation Occurring in Sheets; Patchy Crusting…
N/A N=80 Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®
Radiodermatitis · Quality of Life
Primary: Proportion of Patients Without Grade G2 Skin Toxicity Radiodermatitis at Week 5 — 10; 5; 13; 11 participants
N/A N=72 Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis.
Radiodermatitis · Injury, Radiation
Primary: Number of Participants Categorized by RTOG Grading Scale — 12; 6; 11; 11 Participants
N/A N=25 KeraStat(R) Cream for Radiation Dermatitis
Radiation Dermatitis
Primary: Radiation Therapy Oncology Group Skin Toxicity Scoring — 0.00; 0.00; 0.09; 0.15 score on a scale
N/A N=16 Low Level Laser Therapy for Radiation Induced Dermatitis in H & N Squamous Cell Carcinoma
Radiation Dermatitis
Primary: Grade 3 or Higher Adverse Events — 9 Participants
Phase 1 N=31 Silverlon to Reduce Radiation Dermatitis
Radiation Dermatitis
Primary: Number of Participants With an Adverse Skin Event — 1 Participants
N/A N=28 Study of KeraStat Cream for Radiation Dermatitis During Head and Neck Radiotherapy
Head and Neck Cancer · Radiation Dermatitis
Primary: Completion Rate of Use of KeraStat Cream — 10; 7 Participants
N/A N=70 Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.
Radiodermatitis · Dermatitis, Radiation-Induced
Primary: Number of Participants With Progression of Radio Therapy Induced Skin Reaction — 35; 33 Participants
Phase 3 N=80 Bacterial Decolonization to Prevent Radiation Dermatitis
Radiation Dermatitis
Primary: Number of Participants With Incidence of High Grade Radiation Dermatitis — 0; 9 Participants — p=0.004
N/A N=57 Radiotherapy Related Skin Toxicity: Mepitel® vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer
Head and Neck Neoplasms
Primary: Number of Participants With Grade ≥2 Radiation Dermatitis at 50 Gy (Per Protocol Set) — 3; 9; 6; 18 Participants
Phase 2 N=18 A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
Breast Cancer · Breast Cancer Stage · Breast Cancer Stage I
Primary: Wound Surface Area Reduction of Radiation Dermatitis Grade 2-3 Wound Size From Baseline to Day 14 (+/- 3 Days) — 10.3; 25.3; 0.5; 4.1 cm^2
Phase 3 N=176 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
Breast Cancer · Dermatologic Complications · Radiation Toxicity
Primary: Mean Maximum Grade of Radiation Dermatitis by Treatment Arm. — 1.2; 1.3 Grade — p=0.18
Phase 2 N=6 Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer
Cancer of the Head and Neck
Primary: Rates of Clinically Significant Radiation Dermatitis as Defined as NCI CTCAE Version 5 Grade 2 or Higher — 3; 1 Number of events
Phase 3 N=143 Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Invasive Breast Cancer
Primary: Percentage of Participants With Moist Desquamation — 66.7; 43.8 % of participants w/moist desquamation
Phase 2 N=20 Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Recurrent Melanoma
Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR
Phase 2 N=95 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Metastatic Colorectal Cancer · Skin Rash · Skin Toxicities
Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants
N/A N=32 Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Toxicities
Primary: Qualitative Data From Patients and Experts to Measure Anti-EGFR Therapy-specific Health-related Quality of Life (HRQL) — 2.70; 2.41; 2.70; 2.29 units on a scale
N/A N=20 Normal Tissue Oxygenation Following Radiotherapy
Radiation Toxicity
Primary: Tissue Oxygenation — 62.5 mmHg — p=0.5
N/A N=776 A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Non-melanoma Skin Cancer
Primary: Cure Rate — 751 lesions
N/A N=32 Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
N/A N=11 Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin
Pre-cancerous Geriatric Skin
Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells
N/A N=32 Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT
Breast Cancer
Primary: Success Rate — 65.4 percentage of participants
Phase 2 N=22 RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
Metastatic Melanoma
Primary: Dose-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants